



SANUWAVE

Healing today. Curing tomorrow.

Corporate Overview
SNWV.OB

Rodman & Renshaw
Global Investment Conference
New York Palace Hotel
September 12-15, 2010

Forward-looking Statement Disclaimer

This presentation may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the marketing of the Company's product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, fluctuations in the Company's quarterly results, the Company's ability to continue and manage its growth, liquidity and other capital resources issues, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

Contents

- **SANUWAVE Overview**
- **Technology and Science**
- **Market and Product Review**
- **dermaPACE™- Wound Care Applications**
- **Orthopedic, Cosmetic and Cardiac Applications**
- **Investment Highlights and Corporate Profile**



Company Overview

SANUWAVE is an Emerging Leader in Regenerative Medicine

- **Noninvasive, biologic response activating devices for the repair and regeneration of tissue, musculoskeletal and vascular structures.**
- **Pulsed Acoustic Cellular Expression (PACE™) technology delivers high energy, acoustic pressure waves in the “shockwave” spectrum**
 - Activates biologic signaling at the cellular level and angiogenic responses to restore normal healing processes and regeneration.
- **Focused in four areas: wound, orthopedic/spine, cosmetic and cardiac**
- **Lead product dermaPACE™ addresses the \$10 billion global advanced wound care market**
 - Completed enrollment in pivotal IDE study for first indication, diabetic foot ulcers (DFU).
- **A legacy of commercial development and Class III PMA regulatory success with two approved indications in orthopedics.**
- **Broad patent estate including 50+ issued / pending properties.**

Investment Highlights

- **Proven technology platform with superior efficacy and cost profile**
- **Large and growing wound management market**
 - Competitive product generates >\$1B U.S. revenues
- **Significant product development pipeline with large global markets in orthopedics and aesthetics**
- **Multiple near-term milestones for value creation**
 - Top line data from DFU clinical trial and filing of PMA with the FDA in DFU
 - Initiation of several pivotal studies in a variety of indications
 - Multiple FDA approvals
 - Multiple product launches
 - Continued clinical and science advancements
- **Broad patent estate and protection**
- **Accomplished management with established record of prior success**

Executive Management

Christopher M. Cashman,
Director, President and Chief Executive Officer



Snowden Pencer

Barry J. Jenkins,
Chief Financial Officer



Snowden Pencer

Peter A. Stegagno,
Vice President, Clinical / Regulatory/ Quality



Iulian Cioanta, Ph.D.
Vice President, Research and Development



Bernie Laurel,
Vice President Sales and Marketing



Anne Stefurak
Vice President, Medical Policy and Reimbursement



Established track record guiding medical device companies through approval process, building brand and sales networks and driving profitable growth





Technology and Science

PACE™ Technology

Pulsed Acoustic Cellular Expression (PACE™) technology delivers high energy, acoustic pressure waves in the “shockwave” spectrum


- High pressure amplitudes (500 bar), with rapid rise times (<10ns), a short life cycle (≤ 10 ms), and a frequency spectrum ranging from the audible to the ultrasonic region (16Hz-20MHz.).
- Compressive and tensile stresses cause rapid contraction and distention at the cellular level eliciting a microcellular response.
- Cellular signaling initiate immediate microcirculatory improvement and a significant angiogenic response resulting in the cellular expression of proteins and growth factors.
- Acutely, some of these proteins are cytokines which may effect the inflammatory response, returning a chronic condition to an acute condition and allowing the healing response to re-initiate.
- PACE™ treatments result in increases in several growth factors, including VEGF, which results in neovascularization – an improved blood supply – to the site of treatment.



Typical shock wave (pressure vs. time) of an electrohydraulic system. Schematic representation of the pressure amplitude of the shock wave as a function of time. A positive pressure amplitude ($p+=510$ bar) is followed by a tensile wave ($p=-90$ bar)

Shockwaves – Unlike Other Energy Alternatives


**Focused Shockwaves Produce Compressive Forces
40 - 80 Times Higher Than Ultrasound**




**Shockwaves produce larger cavitation bubbles (more potent),
as compared to minimal cavitation with ultrasound, causing
powerful tensile waves at the cellular level**

PACE™ Biological Effects


Microcirculation Improved



PACE™ mechanical stimulation increases leukocyte (white blood cell) activity resulting in enhanced microcirculation.





Cellular Expression of cytokines and growth factors (such as VEGF, PCNA and eNOS) stimulate endothelium (blood vessel) cell growth and fibroblast proliferation.



Process results in neovascularization allowing improved blood gases and nutrients to enter the treatment area.


Perfusion Increase



Doppler images of a burn injury before and 2 days after PACE™ treatment dramatically demonstrate the increase in circulation that PACE™ treatment achieves as shown by the majority red coloration area.

*Doppler images provided by Meirer et al. Photograph courtesy by Dr. Kristien Van Acker, Diabetic Foot Clinic Bornem, Belgium. Histology provided by Krokowicz L et al Time elapsed photography from Davis TA et al. Extracorporeal Shock Wave Therapy Suppresses the Early Proinflammatory Immune Response to a Severe Cutaneous Burn Injury. International Wound Journal. Vol.6 No.1 2008.


Healing and Long-Term Tissue Viability



Results

- Cell proliferation
- Granulation tissue production
- Re-epithelialization
- Wound closure
- Sustained healing

Neovangiogenesis – New Blood Vessel Growth



VEGF expression indicates new blood vessel formation

- d) Untreated control group
- e) Immediately after PACE™ with 500 impulses
- f) 24 hours after PACE™ with 500 impulses

Histological comparisons between control images and those showing cells after PACE™ indicate greater up-regulation of VEGF on the endothelial cells of the vessels after PACE™.

SANUWAVE

Healing today. Curing tomorrow. 11



Market and Product Review

SANUWAVE

Healing Today. Curing Tomorrow.

Wound Healing

Orthopedic / Spine

Plastic / Cosmetic

Cardiac

dermaPACE™

- Proven established DFU market (\$2B)
- Superior efficacy (>50%) *
- Lower costs (<50%) *
- 80k + amputations / yr

- Diabetic foot ulcer
- Pressure sores
- Burns
- Chronic wounds

orthoPACE™

- PACE™ proven in healing tendinopathies
- Non-union fractures up to 5mm gaps
- Reduce synovitis in arthritic joints
- Angiogenesis supports improvement in bone density

- Osteoarthritis
- Fracture healing
- Osteoporosis
- Spine / neuro application

Profile™

- Massage therapy directed toward cellulite
- Reconstructive microcirculatory preconditioning
- Improvements in skin elasticity
- Potential collagen production

- Cellulite
- Graft and transplant
- Scarring
- Fat ablation

angioPACE™

- Plaque break up for atherosclerosis
- Improved cardiac output
- Adjunct or alternative to bypass surgery
- Address myocardial ischemia

- Revascularization
- Plaque break up
- Peripheral blood supply
- Heart muscle blood supply

Development focus

Targeted uses

* Comparison of PACE™ pilot studies versus published literature.

Disclaimer - Future potential uses. Not approved for use in U.S. Illustrative for investor education and development plans

SANUWAVE

Healing today. Curing tomorrow.

SANUWAVE's patented technology can address multiple, large U.S. markets, exceeding \$10 billion in total

Estimated addressable U.S. market sizes



Source: PACE™ market potential based on estimates from AdvaMed; MEDACorp Analysis, BioMet, Integra LifeSciences and Management



dermaPACE™
Wound Care Applications

Advanced Wound Care Market - Large and Growing

- \$10 billion worldwide Wound Market
 - Diabetic foot ulcers
 - Chronic wounds
 - Pressure wounds/ulcers
 - Burns
- As the U.S. population ages, the incidence of chronic wounds is rising significantly
 - 5 to 7 million chronic and complex wounds projected annually
- 27 million people in the U.S. have diabetes and 54 million are pre-diabetic
 - In excess of 1.5 million diabetic ulcers annually
- 25% of diabetics will acquire a non-healing ulcer in their lifetime
- U.S. dermaPACE™ treatment market estimated at \$2 billion annually
- Hospitalization costs alone of \$16,000 to \$20,000 for a patient with a diabetic foot ulcer
- U.S. diabetic foot ulcers lead to over 82,000 amputations annually at direct and indirect costs ranging from \$20,000 to \$60,000 per patient

PACE™ – Compelling Efficacy in Advanced Wound Healing

Clinical use of PACE™ on all types of chronic wounds has shown superior efficacies to alternative used therapies. Most wounds were chronic three months or greater and other therapy interventions had been attempted without resolution

Summary of Efficacy Findings in Unpublished/Published Reports of Clinical Studies Related to the Use of ESWT in Wound Treatment					
Author	Treatment (Device)	Dose	N (Wound Type)	Follow-Up Time	Efficacy Variable
Kamelger (2005)	ESWT w/EvoTron™ 4 Treatments	500 (0.11 mJ/mm ²)	9 (diabetes-related chronic leg ulcers)	27 days 62 days	Complete Healing 6/9 (67%) >50% Improved 2/9 (22%)
Wang (2007)	dermaPACE™ 6 Treatments (2 series in some cases)	500 (0.11 mJ/mm ²)	42 (diabetic ulcers) > 3 Months	Closure	Complete healing 22/42 (55%) >50% improved 18/42 (43%) No change 2/42 (5%)
Van Acker (2008)	dermaPACE™ 4 Treatments * 3 patients (6x)	500 PACE™ pulses per treatment	12 (diabetic foot ulcers) > 3 months	Closure ≤ 12 weeks	Complete healing 9/12 (75%) >50% improved 2/12 (17%) No change 1/12 (8%)
Medical University, Innsbruck (2007)	ESWT with EvoTron™ 4 Treatments	500 shocks per treatment at 0.07-0.1 mJ/mm ²	14 (diabetic ulcers)	NR	Complete healing 10/14 (71.4%) Incomplete healing 4/14 (28.6%)
	ESWT with EvoTron+ split skin grafting 1-2 treatments		19 (arterial and venous ulcers)	NR	Graft uptake complete 16/19 (84.2%) Graft uptake incomplete 3/19 (15.8%)
	ESWT with EvoTron™ 1 Treatment		5 (deep partial thickness burns)	NR	Complete healing 5/5 (100%)
Moiemen (2008)	dermaPACE™ 2 Treatments	8 impulses per cm ²	10 (mid-deep dermal burns)	Closure	Complete healing 10/10 (100%) No grafting
Barret (2010)	dermaPACE™ 2 Treatments	8 impulses per cm ²	15 (type II and III mixed deep partial to full thickness burns)	Closure	Complete healing 12/15 (80%) No grafting Incomplete healing 2/15 (13%) 1 patient lost to follow up
Schaden (2007)	ESWT w/EvoTron™ 1-10 Treatments	Total of 250 – 6900 impulses; mean of 1764; 0.1 mJ/mm ²	27 (wounds)	NR	Complete Healing 22/23 (95.7%) 50% Improved 1 (4.3%)
Saggini (2007)	ESWT with EvoTron™ 6 Treatments	100 impulses per cm ²	32 (chronic posttraumatic, diabetic and/or venous wounds)	Closure	Complete healing 16/32 (50%) Some closure, granulation and decreased exudates 16/32 (50%)

Note: This is not a complete listing of clinical studies, only a representative chart for discussion purposes.

a) Number of shocks varied by wound size. ESWT=extracorporeal shock wave therapy NR=not reported

U.S. Pivotal Phase III Diabetic Foot Ulcer IDE

- **Study Design:** 200 patient, randomized (1:1), double-blind, sham controlled, multi-center (24) study.
- **Purpose:** Compare the safety and efficacy of the dermaPACE™ device to sham treatment, when administered in conjunction with standard of care, in the treatment of diabetic foot ulcerations.

Primary Objectives:

- Assess incidence of complete wound closure of dermaPACE compared to sham control group 12 weeks post initial treatment.
- Complete wound closure is defined as skin re-epithelialization without drainage or dressing requirements.
- To determine rate of adverse events of the dermaPACE and control groups 24 weeks post initial treatment.

Secondary Objectives:

- Time to reach DFU wound closure between subjects in the dermaPACE and control groups 12 weeks post initial treatment
- DFU wound closure area and volume between subjects in the dermaPACE and control groups 12 weeks post initial treatment
- Pain / return of sensation (using Visual Analog Scale) of the dermaPACE and control groups throughout the 12 weeks post initial treatment
- Assess safety by determining rate of device-related adverse events and device malfunction of subjects treated with dermaPACE throughout the 24 weeks post initial treatment

dermaPACE™ Commercial Plan

- SANUWAVE's business model is a per procedure pricing model
- RFID card readers are built into each generator box
- SANUWAVE will sell procedure kits incorporating procedure specific protocol cards that activate the device
- Standard protocol for a DFU is four (4) treatments of 500 pressure pulses each over a two week period
 - PACE application at days 1 and 4 at week one and days 7 and 11 at week two
- Sell through a direct sales force that incorporates a nurse consultant role as part of the team
- International distribution partners country by country in Europe / Asia

dermaPACE™
Pulsed Acoustic Cellular Expression



SANUWAVE
Healing today. Curing tomorrow.

dermaPACE™ - Diabetic Foot Ulcers

Demonstrated DFU efficacy



August 20, 2007

October 31, 2007

Female 86 years old
Chronic diabetic foot ulcer
Experienced significant pain from wound
Pain resolved during PACE™ protocol
Fully epithelialized

Source: Dr. Van Acker, Belgium
The dermaPACE™ device is currently the subject of an Investigational Device Exemption (IDE) study and is not available or for sale in the United States.



August 20, 2007

October 3, 2007

Male 49 years old
Diabetic Type 2 Osteomyelitis of the big toe
Previous amputation of the toe
Ulcer progressing to further amputation
4 PACE™ treatments (2x each week)
Resolved fully

dermaPACE™ - Diabetic Foot Ulcers



Chronic Diabetic Ulcer greater than 6 months
Pictures at Day 1 and Day 15. Four treatments of 500 pulses over 2 weeks

Source: Medical University
of Innsbruck

The dermaPACE™ device is currently the subject of an Investigational Device Exemption (IDE) study and is not available or for sale in the United States.

dermaPACE™ - Wound Healing

- 70-year old man with 1-year old venous wound with extreme lymphatic swelling
- Four PACE™ treatments over two week period of 500 pressure pulses each
- Non-responsive to multiple other adjunct therapies tried during course of one year
- Complete closure at 5 weeks with improved lymphatic circulation

**Source: Dr. Hintringer, Chief of Plastic and Reconstructive Surgery
Linz, Austria**


The dermaPACE™ device is currently the subject of an Investigational Device Exemption (IDE) study and is not available or for sale in the United States.




dermaPACE™ - Burn Treatment

In excess of one million U.S. burn cases annually, leading to over 700,000 emergency room visits and 45,000 hospitalizations

- Deep partial thickness burns on right forearm sustained while cooking with hot oil
- Patient refused skin grafting for cosmetic reasons
- Treated the burn area at days 3 and 7 after injury with 1,500 pressure pulses
- The six month follow-up revealed uneventful healing without scarring



Before initial treatment



Before 2nd Treatment



48 Hours after the accident



Day 15, nearly epithelialized



Six months after burn

Deep partial thickness burns characteristically take longer than 21 days to heal and scarring may be severe

Source: An Innovative Treatment Method for Partial Thickness Burns, Meirer/Kamelger/Piza, Leopold-Franzens University, Medical University of Innsbruck, Ludwig-Boltzmann-Institute for Quality Control in Plastic and Reconstructive Surgery

The dermaPACE™ device is currently the subject of an Investigational Device Exemption (IDE) study and is not available or for sale in the United States.

dermaPACE™ - Trauma Treatment

16 year old subject of motorcycle accident resulting in complex foot trauma. Initially treated with surgery and NPWT. Began dermaPACE™ treatments at Day 34 due to wound not healing.



Day 34 – Post Trauma



Day 34 – 1st Treatment



Day 45 – 3rd Treatment



Day 53 – 5th Treatment



Day 69



Day 183

Source: Kalmeger, M.D.
Innsbruck Medical
Center


The dermaPACE™ device is currently the subject of an Investigational Device Exemption (IDE) study and is not available or for sale in the United States.

PACE™ Efficacy – Disruptive Science

Significantly better efficacy, improved care
Shorter healing times than existing therapies

- PACE™ efficacy rates are significantly higher at 12 weeks
- PACE™ protocol allows for better patient compliance – only four treatments in 2 weeks
 - Do not wear 24 hours per day for 2 to 4 months (NPWT)
 - Do not have 3 visits/wk for 12 wks+ (ultrasound)
 - No repeat surgeries or tissue replacement

Efficacy Rates at 12 Weeks for the Treatment of DFU*



*Data on File – Based on published reports/literature. PACE™ results based on pilot, DFU studies outside U.S.


The dermaPACE™ device is currently the subject of an Investigational Device Exemption (IDE) study and is not available or for sale in the United States.

PACE™ - Compelling Cost and Convenience

Potentially, less than half the cost of existing therapies

- PACE™ is less expensive and burdensome on provider and patient
- No NPWT revenue for physician in current home healthcare model
- PACE™ does not require constant home healthcare provider visits (every 2 to 3 days) and recurring office visits

Advanced Modality Cost Comparison for DFU Treatment



■ Estimated costs associated with full 12 weeks of DFU treatment including physician and nursing time, facility charges, treatment costs and associated standard of care.

*Data on File – Based on published reports/literature
PACE™ costs assume four treatments

The dermaPACE™ device is currently the subject of an Investigational Device Exemption (IDE) study and is not available or for sale in the United States.




Orthopedic, Cosmetic and Cardiac
Applications

Orthopedic Regeneration Market- orthoPACE™



Trauma
- Long bone / extremity



Osteoarthritis
- Knee




Sports Medicine
- Tendinopathy
- Pain



Spine / Neuro
- Fusion
- Nerve repair

Biological Signaling Evidence

- Increases in cellular signaling were apparent during Dr. Wang's mechanism of action research study. Biological markers that would indicate healing, including eNOS (benefits oxygenation), VEGF (increases blood flow) and PCNA (increases cellular proliferation), increased after treatment.
- The effects lasted up to 12 weeks before declining to normal levels. In comparison, the control samples did not demonstrate any positive cellular changes during the study.*



* Wang et al. Shock Wave Therapy Induces Neovascularization at the Tendon-Bone Junction. Journal of Orthopaedic Research, 21 (2003) pp. 984-989.
Note: The orthoPACE™ device is currently not available or for sale in the United States

SANUWAVE

Healing today. Curing tomorrow. 28

PACE™ – Compelling Efficacy in Orthopedic Healing

Clinical use of PACE™ on all types of orthopedic conditions has shown superior efficacies to alternative used therapies, decreased the need for surgical intervention and is more cost effective than other modalities.


Summary of Efficacy Findings in Published Reports of Clinical Studies Related to the Use of ESWT in Orthopedic Treatment					
Author	Treatment (Device)	Dose	Orthopedic Indication	Follow-Up Time	Efficacy Variable
Schaden (1998-2004)	ESWT w/OssaTron® 80% - 1 Treatment 15% - 2 Treatments 5% - 3 Treatments 1 patient - 4 Treatments	4000-12000 (0.38-0.40 mJ/mm ²)	172 Nonunion Fractures	4.8 +/- 4.0 months	Complete boney union 138/172 (80.2%) Incomplete union 34/172 (19.8%)
Wang (2001)	ESWT w/OssaTron® 1 Treatment	1000-6000 depending on bone type, (20kV-28kV)	72 Nonunion Fractures	12 months	Excellent/Good 58/72 (80%)
Ogden (2003)	ESWT w/OssaTron® 66% - 1 Treatment 34% - 2 treatments	1500 (0.27 mJ/mm ²)	302 Proximal Plantar Fasciitis	12 weeks	Excellent/Good (76%)
Santos (2001-2007)	ESWT w/Reflectron™ 1 Treatment	1200-1500, 20mm depth (0.14 mJ/mm ²)	297 Chronic Plantar fasciitis (heel pain)	180 days	Excellent/Good 228/297 (76.8%) Acceptable 24/297 (8.1%) No change 45/297 (15.1%) Worsening 0/297 (0%)
Lui (2009)	ESWT w/Reflectron™ 1 Treatment	1000, 5mm depth (0.13 mJ/mm ²)	16 Chronic Patellar Tendinopathy	180 days	Excellent/Good 12/16 (75%) Poor 4/16 (25%)
Rocket (2002-2007)	ESWT w/Reflectron™ 79% - 1 Treatment 15% - 2 Treatments 6% - 3 Treatments	1000, 5mm depth (0.13 mJ/mm ²)	156 Chronic Achilles Tendinopathy	180 days	Excellent/Good 108/156 (69.2%) Acceptable 24/156 (15.4%) Poor 24/156 (15.4%)
Cross (1998-2002)	ESWT w/OssaTron®	1500 (18kV)	165 Chronic Lateral Epicondylitis (tennis elbow)	56 days	Excellent/Good/Fair 149/165 90% Poor 16/165 (10%)
Santos (2002-2004)	ESWT w/Reflectron™ 94% - 1 Treatment 6% - 2 Treatments	1200, 35mm depth (0.14 mJ/mm ²)	32 Hip Bursitis	180	Excellent/Good 28/32 (87.5%) Acceptable 4/32 (12.5%) Poor 4/32 (12.5%)
Wang (2008)	ESWT w/OssaTron® 1 Treatment	6000 (0.62 mJ/mm ²)	30 Avascular Necrosis (Hip)		Improved 25/30 (83%) Unchanged 2/30 (7%) Worsened/hip replacement 3/30 (10%)

Note: This is not a complete listing of clinical studies, only a representative chart for discussion purposes.


ESWT=extracorporeal shock wave therapy NR=not reported

Cosmetic - Profile™ May Positively Affect Aesthetic Uses

- Profile applies Diffused Acoustic Pressure (DAP™) which may help with post surgical healing, pain and scar management
- Extracellular signal transduction generating NO-radicals and HSPs
- May have a significant effect on strengthening and tightening skin's scaffold and density within the dermis and subcutaneous fat



Derma Scan image: 54 yr old female cellulite skin*



-Before therapy (A), the skin is less compact (the black structures are fat cells and lymphatic fluid).

- After therapy (B), the skin tissue has become measurably more compact, indicating a strengthening of the connective tissue.

* Christ C, Rainer B, Sattler G, Werner S, Novak P, Daser A. Improvement in Skin Elasticity in the Treatment of Cellulite and Connective Tissue Weakness by Means of Extracorporeal Pulse Activation Therapy. Aesthetic Surgery Journal. Vol 28, No 5, Sept/Oct 2008.

Note: The aesthetic product line is currently not available or for sale in the United States

Reduction in the Look and Feel of a Post-Surgical Scar

Patient presented a few days after an abdominoplasty and laser liposuction procedure with a traumatic skin injury and early scar formation.



4/5/2010



7/12/2010



- A few weeks after presentation, the patient began receiving Profile™ treatments.
- After seven (7) Profile™ treatments, the internal scar area, resulting from the laser liposuction procedure, softened and became less noticeable. This is most likely due to tissue reorganization, collagen production stimulation and lymphatic stimulation caused by Profile™ treatment.
- This patient is continuing Profile™ treatment with ongoing improvement.

SANUWAVE
Healing today. Curing tomorrow.

Reduction in the Look and Feel of a Post-Surgical Scar

Patient underwent bariatric surgery followed by a body lift to remove excess skin. The patient presented six months post-operatively with a beltline incision scar resulting from the body lift procedure.



- After 16 Profile™ treatments over eight weeks, the scar showed noticeable flattening, smoothing and softening.
- The hyper pigmentation areas of dark coloration have lessened in response to Profile™ treatment as well.

Cardiac – Development for the Future

- 5.7 million people are living with heart failure; 670,000 new cases each year
- Current treatments for ischemic heart disease
 - Medication
 - Percutaneous coronary intervention (PCI); 1.3 million/year*
 - Coronary artery bypass grafting (CABG); 880,000/year*
- Researching and developing next generation devices to remove plaque in coronary arteries and improve blood supply/ revascularize heart muscle
- Strategic partner and licensing opportunities once basic proof of concept completed
- Provisional patents filed



* American Heart Association



Investment Highlights Corporate Profile

Timeline of Events

- | | |
|------------------------------|--|
| Q1 2010 | ✓ Completed dermaPACE™ DFU IDE enrollment (206 patients) |
| Q2 2010 | ✓ orthoPACE™ EU commercial launch |
| Q3 2010 | ✓ dermaPACE™ DFU IDE follow up complete |
| Q4 2010 | <ul style="list-style-type: none">• Submit dermaPACE™ DFU PMA manufacturing module• Aesthetic product (Profile™) WW commercial launch |
| Q4 2010 / Q1 2011 | <ul style="list-style-type: none">• Release top line dermaPACE™ DFU data• Submit dermaPACE™ DFU PMA clinical package |
| Q2 / Q3 2011 | <ul style="list-style-type: none">• dermaPACE™ DFU FDA response |
| Q3 / Q4 2011 | <ul style="list-style-type: none">• dermaPACE™ DFU PMA approved |
| PMA approved plus 1-2 months | <ul style="list-style-type: none">• dermaPACE™ DFU U.S. commercialization |

Corporate Profile

- Ticker SNWV.OB
- Shares Outstanding 12.5 million
- Share Price (9/07/2010) \$3.00
- Warrants: Number 2.8 million
Exercise Price \$5.57 weighted average
- Employees 28
- Market Capitalization \$37.5 million

Investment Highlights

- **Proven technology platform with superior efficacy and cost profile**
- **Large and growing wound management market**
 - Competitive product generates >\$1B U.S. revenues
- **Significant product development pipeline with large global markets in orthopedics and aesthetics**
- **Multiple near-term milestones for value creation**
 - Top line data from DFU clinical trial and filing of PMA with the FDA in DFU
 - Initiation of several pivotal studies in a variety of indications
 - Multiple FDA approvals
 - Multiple product launches
 - Continued clinical and science advancements
- **Broad patent estate and protection**
- **Accomplished management with established record of prior success**